| Hans-Günter Meyer-Thompson | Buprenorphin
SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS)
SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioidantagonist)
Initial REMS approval: 08/2010, Most recent modification: 04/2014 NDA 22‐410
Reckitt Benckiser Pharmaceuticals Inc.